Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00094666 |
The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.
Condition | Intervention | Phase |
---|---|---|
Primary Insomnia |
Drug: MK0928, gaboxadol / Duration of Treatment - 6 weeks Drug: Comparator: placebo / Duration of Treatment - 6 weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
United States, Florida | |
Call for Information | |
Hallandale Beach, Florida, United States, 33009 | |
United States, New York | |
Call for Information | |
Williamsville, New York, United States, 14221 |
Study Director: | Medical Monitor | Merck |
Study ID Numbers: | 2004_085 |
Study First Received: | October 21, 2004 |
Last Updated: | March 28, 2007 |
ClinicalTrials.gov Identifier: | NCT00094666 |
Health Authority: | United States: Food and Drug Administration |
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol Sleep Initiation and Maintenance Disorders Mental Disorders |
Dyssomnias Sleep Disorders Sleep Disorders, Intrinsic |
Nervous System Diseases |